Inmagene to Participate in the Jefferies Healthcare Conference on June 8

SAN DIEGO,SHANGHAI and SYDNEY,May 30,2023 --Inmagene Biopharmaceuticals ("Inmagene"),a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases,today announced that management has been invited to participate in the Jefferies Healthcare Conference,which will be held in New York from June 7-9,2023.

Dr. Jonathan Wang,Chairman and Chief Executive Officer of Inmagene,will present on Thursday,June 8,at 8:00-8:25 AM. A webcast of the presentation can be accessed at the following site: https://wsw.com/webcast/jeff281/inma/1837550

Dr. Wang and Dr. Yufang Lu,Chief Medical Officer of Inmagene,will hold meetings with investors and potential partners to discuss investment and partnering opportunities.

About Inmagene Biopharmaceuticals

Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. It has four clinical-stage drug candidates. The leading compound,izokibep (IMG-020),is in global clinical development for 5 indications,including 2 pivotal trials for psoriatic arthritis (PsA) and hidradenitis suppurativa (HS). The second compound,IMG-007,an OX40 receptor antagonist monoclonal antibody (mAb) with a silenced ADCC function,is entering 2 global Phase 2 clinical trials. The third compound,IMG-004,a non-covalent,reversible,and brain-permeable BTK inhibitor (BTKi),with a longer PD effect (over 72 hours) than most leading BTKis,is finishing Phase 1 clinical studies. Finally,IMG-008,a long-acting mAb against IL-36R,with over 4x half-life and over 2x exposure of spesolimab,is entering global Phase 1 clinical development.

Based on its proprietary QuadraTek® platform,Inmagene creates and develops novel drug candidates with global rights. The company also in-licenses drug candidates and,together with its partners,carries out global development activities,including global multi-center clinical trials. Inmagene has formed strategic partnerships with multiple partners,such as HUTCHMED and Affibody AB,to develop highly innovative drug candidates.